Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System

Regarding Aerosil, the increase in the particle size can be explained in terms of the affinity of Aerosil to agglomerate at high coPnhcaremnatcreauttiicos n20a19n,d11t,hxiFsOiRs iPnEEhRaRrmEVoIEnWy with the results reported by Varshosaz et al

Ibrahim Elsayed

2019

Scholarcy highlights

  • Rosuvastatin calcium is an hydroxymethylglutaryl-coenzyme A reductase inhibitor used in the treatment of hyperlipidemia
  • Regarding Aerosil, the increase in the particle size can be explained in terms of the affinity of Aerosil to agglomerate at high coPnhcaremnatcreauttiicos n20a19n,d11t,hxiFsOiRs iPnEEhRaRrmEVoIEnWy with the results reported by Varshosaz et al
  • 3.4.2.CInapVsiutrleosRwCeRreeelenatseerifcr-ocmoathede Etontreerlieca-sCeotahtedwChaoplesudlreusg dose only in the small intestine where ppptaod6ccstaoacohhioiacctffbrHoemt]fteoiesooietioae.lorntemiln6nissnfeemuttrOgbee.tthyrd6iibe1ededucziine)Orc4ilrno.eOffrlaicittfitcAdtcFcooroebteFhh--EiyoMracrectfAaebbsauiyototo(ncoieewtaodgprta-afdffomtctontartdHdene,hooeEacriepiiddudfFeagmrrtunirp6oeelrtiicdceaOceg.tucrcra6aehvatdertutLlnFi)oapllaepaavo.ryy1Atcftgnsntseeno0hiui1iutAandaons0t7fl4bbrlRtn,o,oceBerLesssrsbswFCefrRsloo1ei,melerigsCtsea0hrrgeacrthhnhbbas0uweoiuvseoceeisero,ellmerfiheeeweaddwewaioatlecdtnplewheipsan7tetshoaahhdeeatndtBaihrnsteilrrctsmiehwlezoeoasznrhdetei,uecueuhidinhrhtzvnrwcsggrtoohcreoeeooeehuhrloeatddalmlererhgfoetselettsahaasdeahhtpfltlrsueheosseodreeeetasasearuehmlaemrtemseppsiogeendpoednaeaooadmuprsrcdedirrriotaeenlhtnnkttatohrafislaao.eumtrcieste00llelaiThteaage.o.trcict1d1nsh.hpszienoiiwecrrirerNeNnsoseTauccodcpilfnnuumthgcdoayHHrhtdfRlolinauoeaaaosiriuCCtCdnfirnctteerr,iliictklmxlllowdco2,oe,etftetanhnhr0aiiseuuchtbnnnoesenollmteoetdpmddedaotoasrfmritiaietmwtrccionbRtt,thtoaaaahhithdeaawCtetnrtwtreeeesuliiikdsalnbnhdhcflloecitagiuiaigrertstitnovbvnoulnrrtsteatatseeeeipmdogdhhebentrrdolrseeeriuvdepott((tndvtthtittexcchdoolnehdhetseaatycewudhdeeeeitppaasmchn2ecdpaawwstsstt9eoto.bioiebasdp.ttiahrulwr0ipieTetHrvllt,tkeh5liuHiehhaeetoroite%dnygy≥aeeesssff-t optimized formulations released all the loaded drug within 20 min while only 29.05% was released from the market product and 25.44% from the capsules loaded with the drug powder
  • Significant improvements in the drug dissolution rate were observed in the optimized In situ forming nanovesicular systems formulations when compared to the market RC product
  • Drug bioavailability was increased three times in the case of the IFN optimized formula loaded on Aerosil
  • The high flowability of the prepared IFN facilitated the recovery of more than 95% of the utilized excipients
  • IFN can be considered as a promising nanocarrier to enhance the oral bioavailability of BCS class II drugs suffering from a low solubility in physiological media
  • In situ forming nanovesicular systems can be considered as a promising nanocarrier to enhance the oral bioavailability of BCS class II drugs suffering from a low solubility in physiological media

Need more features? Save interactive summary cards to your Scholarcy Library.